![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChemCID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C28H34N2O |
Molar mass | 414.593 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
GBR-12935 is apiperazine derivative which is a potent and selectivedopamine reuptake inhibitor. It was originally developed in its3Hradiolabelled form for the purpose of mapping the distribution of dopaminergic neurons in the brain by selective labelling ofdopamine transporter proteins.[1] This has led to potential clinical uses in the diagnosis ofParkinson's disease,[2] although selective radioligands such asIoflupane (123I) are now available for this application. GBR-12935 is now widely used in animal research into Parkinson's disease and the dopamine pathways in the brain.[3][4][5]
![]() | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |